Salix Pharmaceuticals, Ltd. Share Price

Stocks

17/15/17	Endo : Valeant trumps Endo with $10.96 billion bid for Salix Pharma	RE
17/15/17	Bank of Montreal : TSX climbs on upbeat sentiment ahead of Fed meeting	RE
17/15/17	Wall St. bounces as dollar drops, Fed worries ease	RE
16/15/16	Endo : withdraws offer for Salix	RE
12/15/12	Valeant Pharmaceuticals Intl : TSX rebounds as energy shares advance with oil price	RE
05/15/05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
05/15/05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
05/15/05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
24/15/24	Shire : buys Meritage Pharma for at least $70 million	RE
24/15/24	Canadian Natural Resources : TSX gains on Valeant news; financial stocks weigh	RE
24/15/24	Boeing : Nasdaq ends up 9th session; S&P 500, Dow dip with energy	RE
23/15/23	BioMarin Pharmaceutical : Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources	RE
22/15/22	Salix Pharmaceuticals : Valeant nears deal to buy Salix for about $10 billion - WSJ	RE

12/15/12	Salix Pharmaceuticals : Confirms Receipt of an Unsolicited Proposal from Endo International plc	BU
03/15/03	Salix Pharmaceuticals : Reports 4Q2014 and FY2014 Results	BU
27/15/27	Salix Pharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	PR
26/15/26	Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 1.5% Convertible Senior Notes Due 2019	BU
26/15/26	Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 2.75% Convertible Senior Notes Due 2015	BU

02/15/02	Valeant Pharmaceuticals Intl : Le laboratoire canadien Valeant conclut l'acquisition de Salix
30/15/30	Sanofi ne juge pas des acquisitions "indispensables"-Pdt
17/15/17	Le recul du dollar a favorisé le rebond de Wall Street
16/15/16	Allergan : Valeant relève son offre sur Salix, Endo jette l'éponge
16/15/16	BlackBerry : Les valeurs à suivre sur les marchés américains

Manager	Title	Age	Since
Josh Coyle SAM	Sales & Marketing	-	01/01/2018
John Temperato SAM	Sales & Marketing	61	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALIX PHARMACEUTICALS, LTD.	-.--%	+0.16%	-	-	0
MERCK & CO., INC.	+1.79%	+3.21%	+83.41%	+40.07%	36TCr
MERCK KGAA	+2.12%	+1.57%	+22.49%	-17.38%	6.47TCr
HALOZYME THERAPEUTICS, INC.	-0.89%	+3.25%	+43.23%	+179.25%	1.28TCr
KYOWA KIRIN CO., LTD.	-0.29%	+1.37%	-4.00%	-15.28%	752.5Cr
SK BIOPHARMACEUTICALS CO., LTD.	-0.13%	-1.90%	-31.63%	-10.80%	438Cr
YUHAN CORPORATION	-0.40%	-4.42%	-36.26%	+8.44%	407.65Cr
BETTA PHARMACEUTICALS CO., LTD.	+4.64%	+5.71%	-26.33%	-8.42%	296.44Cr
SUPERNUS PHARMACEUTICALS, INC.	+1.86%	+3.11%	-7.08%	+54.83%	244.13Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+2.77%	+2.54%	-21.46%	-33.39%	192.58Cr
Average	+1.15%	+2.06%	+2.49%	+21.93%	5.15TCr
Weighted average by Cap.	+1.71%	+2.89%	+68.61%	+33.68%

Employees

Sector